Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (31-40 of 247) with videos related to

Pageof 25
Sort By:
Microbes and Infection|November 19, 2023
Middle East respiratory coronavirus (MERS-CoV) internalized by llama alveolar macrophages does not result in virus replication or induction of pro-inflammatory cytokinesJordi Rodon, Martin Sachse, Nigeer Te, et al.
Cancer Treatment Reviews|February 24, 2017
The expanding role of immunotherapyJuan Martin-Liberal, María Ochoa de Olza, Cinta Hierro, et al.
International Journal of Medical Informatics|September 5, 2020
Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effortAlejandro Araya, Jia Zeng, Amber Johnson, et al.
Plos Pathogens|May 24, 2021
Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are features of alpacas resolving MERS-CoV infectionNigeer Te, Jordi Rodon, Maria Ballester, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)Jordi Rodon, Charlotte D Jacobs, Quincy Chu, et al.
Investigational New Drugs|September 11, 2020
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancerAnalía Azaro, Capucine Baldini, Jordi Rodon, et al.
Oncoscience|January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision makingSmruti J Vidwans, Michelle L Turski, Filip Janku, et al.
British Journal of Cancer|August 4, 2020
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumoursJuan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos, et al.
Plos One|October 25, 2011
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axisHelen J Huang, Laura S Angelo, Jordi Rodon, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Pageof 25

Showing results (31-40 of 247) with videos related to

Sort By:
Pageof 25
Microbes and Infection|November 19, 2023
Middle East respiratory coronavirus (MERS-CoV) internalized by llama alveolar macrophages does not result in virus replication or induction of pro-inflammatory cytokinesJordi Rodon, Martin Sachse, Nigeer Te, et al.
Cancer Treatment Reviews|February 24, 2017
The expanding role of immunotherapyJuan Martin-Liberal, María Ochoa de Olza, Cinta Hierro, et al.
International Journal of Medical Informatics|September 5, 2020
Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effortAlejandro Araya, Jia Zeng, Amber Johnson, et al.
Plos Pathogens|May 24, 2021
Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are features of alpacas resolving MERS-CoV infectionNigeer Te, Jordi Rodon, Maria Ballester, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)Jordi Rodon, Charlotte D Jacobs, Quincy Chu, et al.
Investigational New Drugs|September 11, 2020
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancerAnalía Azaro, Capucine Baldini, Jordi Rodon, et al.
Oncoscience|January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision makingSmruti J Vidwans, Michelle L Turski, Filip Janku, et al.
British Journal of Cancer|August 4, 2020
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumoursJuan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos, et al.
Plos One|October 25, 2011
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axisHelen J Huang, Laura S Angelo, Jordi Rodon, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Pageof 25